[logo] HealthTree Foundation
search more_vert
close
person Sign In / Create Account
arrow_back

Go back to trials list

Phase 1b/2, Open-Label Study to Evaluate Safety and Tolerability of Epcoritamab in Combination With Anti-Neoplastic Agents in Subjects With Non-Hodgkin Lymphoma


Description

B-cell Lymphoma is an aggressive and rare cancer of a type of immune cell (a white blood cell responsible for fighting infections). The purpose of this study is to assess the safety and tolerability of epcoritamab in combination with anti-neoplastic agents in adult participants with Non-Hodgkin lymphoma (NHL). Adverse events and change in disease activity will be assessed. Epcoritamab is an investigational drug being developed for the treatment of NHL. Study doctors put the participants in groups called treatment arms. The combination of epcoritamab with anti-neoplastic agents will be explored. Each treatment arm receives a different treatment combination depending on eligibility. Approximately 622 adult participants with NHL will be enrolled in 100 sites globally. In both the dose escalation and dose expansion arms participants will receive subcutaneous (SC) epcoritamab in 28 day, 21 day, or 56 day cycles dependent on the arm in combination with the anti-neoplastic agents described

Trial Eligibility

Inclusion Criteria: * Diagnosis of: -- Diffuse large B-cell lymphoma (DLBCL) (de novo or histologically transformed from follicular lymphoma (FL) or nodal marginal zone lymphoma) with histologically confirmed CD20+ disease at most recent representative tumor biopsy pathology report, inclusive of the following according to World Health Organization (WHO) 2016 classification and documented in pathology report: * DLBCL, not otherwise specified (NOS). * High-grade B cell lymphoma with MYC and BCL-2 and/or BCL-6 translocations per WHO 2016 ("double-hit" or "triple-hit") Note: High-grade B-cell lymphomas NOS or other double- /triple-hit lymphomas (with histologies not consistent with DLBCL) are not eligible. * Follicular lymphoma (FL) Grade 3B. OR * FL with histologically confirmed CD20+ Grade 1 to 3a and no evidence of histologic transformation to an aggressive lymphoma at most recent representative tumor biopsy, according to WHO 2016 classification. OR * Mantle cell lymphoma (MCL) with histologically confirmed CD20+ disease at most recent representative tumor biopsy according to the WHO 2016 classification with evidence of overexpression of cyclin D1 in association with relevant markers or evidence of t(11;14) assessed by flow cytometry, FISH, or polymerase chain reaction (PCR). * Eastern Cooperative Oncology Group (ECOG) performance status 0 - 2, except for Arms 6, 7, and 8 where ECOG performance status must be 0-1. * Must have 1 or more measurable disease sites: * A positron emission tomography (PET) /computed tomography (CT) scan demonstrating PET-positive lesion(s) AND * At least 1 measurable nodal lesion (long axis \> 1.5 cm) or \>= 1 measurable extra-nodal lesion (long axis \> 1.0 cm) on CT scan or magnetic resonance imaging (MRI). Exclusion Criteria: * Prior treatment with epcoritamab or any other bispecific antibody targeting CD3 and CD20. * Toxicities from prior anticancer therapy, defined as having not resolved to Common Terminology Criteria for Adverse Events (CTCAE, v 5.0), Grade 2 or below, with the exception of alopecia. Other eligibility criteria (e.g., laboratory, cardiac criteria) must also be met.

Study Info

Organization

Genmab


Primary Outcome

Number of Participants with Dose-Limiting Toxicities (DLT)


Outcome Timeframe Up to Approximately 5 Years

NCTID NCT05283720

Phases PHASE2

Primary Purpose TREATMENT

Start Date 2022-06-14

Completion Date 2031-06-26

Enrollment Target 622

Interventions

DRUG Epcoritamab

DRUG Lenalidomide

DRUG Ibrutinib

DRUG Rituximab

DRUG Cyclophosphamide

DRUG Doxorubicin Hydrochloride [HCl]

DRUG Prednisone

DRUG Polatuzumab Vedotin

DRUG Venetoclax

DRUG CC-99282

DRUG Pirtobrutinib

Locations Recruiting

University of Arizona Cancer Center - North Campus /ID# 242219

United States, Arizona, Tucson


Yale University School of Medicine /ID# 242089

United States, Connecticut, New Haven


Christiana Care Health Service /ID# 242301

United States, Delaware, Newark


Tampa General Hospital /ID# 246748

United States, Florida, Tampa


Emory University /ID# 242153

United States, Georgia, Atlanta


Interested in joining this trial?

Our dedicated patient navigators are here to guide you through the validation and enrollment process with ease.

newsletter icon

Get the latest thought leadership on your Hodgkin Lymphoma delivered straight to your inbox

Subscribe to the weekly newsletter for news, stories, clinical trial updates, and helpful resources and events with cancer experts.

Thanks to our HealthTree Community for Hodgkin Lymphoma Sponsors:

Regeneron
Bristol Myers Squibb